An application running on Android smart devices has been developed in Finland, the purpose of which is to help identify the symptoms of sleep apnea at home. ApneaTracker, which is in the testing phase, is not a medical device, but it can provide information to help more people with sleep apnea seek treatment.

The application, developed at Aalto University, monitors the user's snoring through a microphone and the sleeping position using the sensors of a smartphone or clock. The aim is to detect sleep apnea, which is a typical symptom of sleep apnea. The app also alerts you to change position if snoring or intermittent snoring caused by apnea occurs while the user is sleeping on their back. In the morning, the app generates an overall result of the night’s events with graphical graphs.

Snoring monitoring can also be a limitation of the application, as some people with sleep apnea do not snore. However, many do. According to the developers, the app is suitable for anyone who suspects they may be suffering from the symptoms of sleep apnea or simply wants to follow sleep. According to them, untreated sleep apnea is a serious health risk.

  • Also read: Recognize signs of sleep apnea - one in three patients is of normal weight

ApneaTracker is backed by Aalto University's Joni Gardemeister, Jonatan von Martens and Sowrov Doha, as well as clinical neurophysiology specialist and docent Tapani Salmi. They acknowledge that home measurements cannot be verified under optimal task conditions, but on the other hand, repeated measurements over many nights will help to compensate for this and improve the reliability of the results.

During the testing phase, the app can be downloaded to your Android device for free, but in the future its add-ons will be charged. You can find the app in the Google Play store by searching for it by app name. The name of the developer is SmartValleyW. Note that test versions of applications may be unstable.

Sleep apnea is a disease classified as a public disease that, according to some studies, affects as many as ten percent of the population. As many as nine out of ten cases remain undiagnosed.